Aventis, Barr Battle Over Generic Allegra.(Barr Laboratories, Aventis Pharma)(Brief Article)

Chemical Market Reporter, July, 2001

BARR LABORATORIES Inc. plans to challenge the patents protecting Allegra (fexofenadine), the anti-allergy drug by Aventis Pharma AG. The action follow Barr's filing of an abbreviated new drug application (ANDA) with the Food & Drug Administration (FDA) seeking authorization to produce and market generic 60 mg capsules of Allegra in the US. Allegro had global sales of [epsilon]l.l6 billion ($977.5 million) in 2000 and US sales of [epsilon] 1.03 billion.

In the US, Aventis holds patents on Allegra for method of use, formulation, process and composition. Aventis Pharmaceuticals is evaluating its legal options and intends to defend its intellectual property rights against infringement.

If litigation is pursued, marketing of an FDA-approved generic...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here